Bristol Myers Squibb (BMS) have organised and funded a virtual webinar to shine a spotlight on changing pathology practice in resectable non-small cell lung cancer (NSCLC). [7356-GB-2300663 | September 2023]

TOPICS COVERED

This webinar will delve into a range of topics crucial to today’s rapidly evolving pathology practice in NSCLC. We will explore optimal tissue processing techniques to optimise molecular testing for patients with early- stage resectable NSCLC, and investigate determination of pathologic response and its clinical applicability in the neoadjuvant pathway. Our expert faculty will be answering your questions on how best to implement these evolving practices in your own service.

[7356-GB-2300663 | September 2023]

WHO SHOULD ATTEND?

This meeting is intended for qualified pathologists based in Great Britain only, particularly qualified pathologists with a special interest in lung cancer.

[7356-GB-2300663 | September 2023]

SPEAKERS

• Professor Keith Kerr, Consultant Pathologist, University of Aberdeen (Chair)
• Dr Matt Evans, Consultant Pathologist, University Hospital Southampton
• Dr David Moore, Consultant Thoracic and Molecular Pathologist, UCLH Foundation Trust

[7356-GB-2300663 | September 2023]

This webinar is organised and funded by BMS and is intended for Great Britain healthcare professionals only. BMS medicines and/or product information may be discussed at the meeting. Prescribing information and adverse event reporting will be available from the virtual meeting.

[7356-GB-2300663 | September 2023]